Study guide
12.1 Asthma
Arab Board Pediatrics Part 1 Written Examination ABHS
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current ABHS Pediatrics Part 1 Exam Facts 1.2 How to Use This Guide & Part 1 Study Strategy
2 Neonatal Care I
2.1 Delivery-Room Management & Neonatal Resuscitation 2.2 Prematurity & Complications of Prematurity 2.3 Neonatal Jaundice & Hyperbilirubinemia
3 Neonatal Care II
3.1 Neonatal Sepsis & Infections 3.2 Neonatal Hypoglycemia & Metabolic Problems 3.3 Common Newborn Problems, Birth Injury & Screening
4 Infectious Diseases
4.1 Fever Without a Source & Sepsis Evaluation 4.2 Viral Exanthems & Common Childhood Infections 4.3 TORCH & Congenital Infections 4.4 Tuberculosis & Chronic/Unusual Pediatric Infections
5 Immunization
5.1 Routine Immunization Schedule & Vaccine Science 5.2 Contraindications, Adverse Events & Special Populations
6 Allergy & Immunology
6.1 Primary Immunodeficiency 6.2 Allergic Disease & Atopy
7 Growth & Development
7.1 Developmental Milestones & Red Flags 7.2 Growth Assessment & Failure to Thrive 7.3 Corrected Age & Preterm Follow-Up 7.4 Developmental & Behavioral Disorders
8 Nutrition
8.1 Breastfeeding & Infant Feeding 8.2 Weaning & Malnutrition 8.3 Micronutrient Deficiencies (Rickets, Iron Deficiency)
9 Pediatric Emergencies I
9.1 Pediatric Basic & Advanced Life Support 9.2 Anaphylaxis & Allergic Emergencies 9.3 Poisoning & Toxicology
10 Pediatric Emergencies II
10.1 Septic Shock & the Critically Ill Child 10.2 Upper Airway Emergencies (Epiglottitis, Foreign Body) 10.3 Non-Accidental Injury & Safeguarding
11 Cardiology
11.1 Cyanotic Congenital Heart Disease 11.2 Acyanotic Congenital Heart Disease & Heart Failure 11.3 Innocent Murmurs & Cardiac Evaluation 11.4 Rheumatic Fever & Acquired Heart Disease
12 Respiratory
12.1 Asthma 12.2 Bronchiolitis & Croup 12.3 Foreign Body Aspiration & Other Airway Disorders
13 Gastroenterology
13.1 Pyloric Stenosis & Vomiting Disorders 13.2 Intussusception & the Surgical Abdomen 13.3 Celiac Disease & Malabsorption 13.4 Hirschsprung Disease & Biliary Atresia
14 Nephrology & Genitourinary
14.1 Nephrotic Syndrome 14.2 Glomerulonephritis & Hematuria 14.3 UTI, Enuresis & Genitourinary Anomalies
15 Hematology & Oncology
15.1 Pediatric Anemias (Iron Deficiency, Thalassemia) 15.2 Sickle Cell Disease 15.3 Leukemia & Childhood Malignancies (incl. Wilms Tumor) 15.4 Bleeding & Platelet Disorders (ITP) & G6PD Deficiency
16 Endocrinology
16.1 Diabetes Mellitus & Diabetic Ketoacidosis 16.2 Thyroid & Adrenal Disorders 16.3 Growth Disorders & Puberty
17 Neurology
17.1 Febrile Seizures 17.2 Epilepsy Syndromes & Status Epilepticus 17.3 Bacterial Meningitis & CNS Infections 17.4 Neuromuscular Disorders & Headache
18 Genetics, Dysmorphology & Metabolism
18.1 Chromosomal Disorders & Dysmorphology 18.2 Inheritance Patterns, Consanguinity & Inborn Errors of Metabolism
19 Fluids, Electrolytes & Pharmacology
19.1 Maintenance Fluids & Dehydration 19.2 Electrolyte Disturbances 19.3 Pediatric Pharmacology & Prescribing/Dosing
20 Dermatology, ENT, Ophthalmology & Musculoskeletal
20.1 Common Pediatric Dermatology 20.2 ENT Disorders 20.3 Ophthalmology (Strabismus, Red Eye, Leukocoria) 20.4 Musculoskeletal & Rheumatologic Disorders
21 Adolescent Medicine & Ethics
21.1 Adolescent Health & Puberty 21.2 Ethics, Consent & Professionalism in Pediatrics
22 Final Review & Exam Strategy
22.1 High-Yield Numbers, Mnemonics & Cross-Topic Review 22.2 Exam-Day Strategy & Time Management
12.1 Asthma
Key Takeaways Explain This Topic AI
Diagnosis of asthma under age 5 is clinical (recurrent wheeze/cough pattern, no better alternative cause, and a convincing response to a bronchodilator trial), since spirometry is unreliable before about age 5-6.
The Asthma Predictive Index requires frequent wheezing in the first 3 years of life plus one major criterion (parental asthma, physician-diagnosed atopic dermatitis, aeroallergen sensitization) or two minor criteria (food sensitization, wheeze apart from colds, blood eosinophilia >=4%).
Control, assessed at every follow-up with a simple four-question checklist, drives step-up or step-down therapy decisions; severity is assigned only once, at initial diagnosis before treatment starts.
Inhaled corticosteroids are the controller of choice for chronic inflammation; short-acting beta-2 agonists are relievers only and do not treat the underlying airway inflammation.
Severe exacerbations unresponsive to oxygen, repeated short-acting beta-2 agonist, and systemic corticosteroids warrant IV magnesium sulfate; a pressurized metered-dose inhaler with spacer (plus face mask in young children) is preferred over a nebulizer for mild-to-moderate attacks.
Last updated: July 2026
Diagnosing Asthma in Children Under 5
Asthma is a chronic inflammatory disease of the airways characterized by variable, reversible airflow obstruction, bronchial hyperresponsiveness, and recurrent symptoms of wheeze, cough, chest tightness, and dyspnea. It is the most common chronic disease of childhood, and the written paper tests it heavily because both diagnosis and management change with age.
The core diagnostic problem in preschool children is that spirometry -- the objective lung-function test that confirms variable airflow obstruction by demonstrating a reduced forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio with reversibility after a bronchodilator -- cannot be performed reliably before about age 5-6, because young children cannot cooperate with the forced expiratory maneuver. Diagnosis under age 5 is therefore clinical, based on a pattern of:
Recurrent wheeze, cough, or breathlessness, often triggered by viral upper respiratory infections, exercise, laughing, crying, cold air, or allergen exposure
- Symptoms worse at night or in the early morning
- A personal or family history of atopy (eczema, allergic rhinitis, food allergy, or parental asthma)
A clear symptomatic response to a therapeutic trial of a bronchodilator (often with an inhaled corticosteroid), with relapse when treatment is stopped
Because up to a third of preschoolers wheeze with viral infections and most of them ("transient early wheezers") outgrow it by school age, exam questions favor tools that separate transient wheeze from true asthma. The Asthma Predictive Index (API) is the classic tool: a child with frequent wheezing (four or more episodes in a year) in the first 3 years of life is API-positive if they also have ONE major criterion (parental asthma, physician-diagnosed atopic dermatitis, or aeroallergen sensitization) or TWO minor criteria (food allergen sensitization, wheezing apart from colds, or blood eosinophilia of 4% or more). A positive API strongly predicts persistent asthma at school age.
Severity and Control Classification
Two classifications matter and are frequently confused on exams:
Classification When Used Categories
Severity At initial diagnosis, before treatment Intermittent, Mild persistent, Moderate persistent, Severe persistent
Control At every follow-up visit, once on treatment Well-controlled, Partly controlled, Uncontrolled
Severity is based on symptom frequency, nighttime awakenings, reliever use, and lung function before any controller therapy is started. Control -- the classification used at every follow-up visit -- asks four simple questions about the preceding 1-4 weeks: daytime symptoms more than twice a week, any nighttime waking, reliever use more than twice a week, and any activity limitation. Zero "yes" answers means well-controlled; 1-2 means partly controlled; 3-4 means uncontrolled. The exam frequently rewards recognizing that ongoing management decisions are driven by control , not by the original severity label.
Stepwise Management: Controller vs. Reliever
Asthma medications fall into two functional classes, and mixing them up is a classic exam trap:
Reliever (rescue) medication -- a short-acting beta-2 agonist (SABA) such as salbutamol (albuterol), used as-needed for acute symptom relief. It treats bronchospasm but does nothing for the underlying inflammation.
Controller (maintenance) medication -- chiefly inhaled corticosteroids (ICS), taken daily regardless of symptoms, which treat chronic airway inflammation and are the most effective agents for preventing exacerbations.
Management follows a stepwise ladder that escalates or de-escalates based on the control assessment above:
- Step 1 -- as-needed SABA only (reserved for infrequent, mild symptoms)
- Step 2 -- regular low-dose ICS as a controller, plus as-needed SABA
Step 3 -- low-dose ICS plus a second controller (a long-acting beta-2 agonist [LABA] in older children, or an increased ICS dose in children under 5, who should not receive a LABA)
Step 4-5 -- medium/high-dose ICS-LABA combination, addition of a leukotriene receptor antagonist (montelukast), and referral for severe/refractory asthma (biologic therapy, oral corticosteroids as a last resort)
A leukotriene receptor antagonist such as montelukast is a reasonable alternative controller in young children, particularly for exercise- or virus-induced symptoms, though it is generally less effective than ICS.
Acute Exacerbation Management
Assess severity by respiratory rate, accessory muscle use, ability to speak in sentences, oxygen saturation, and mental status. Initial treatment of a moderate-to-severe exacerbation includes:
Oxygen to keep saturation at 94% or above
Repeated doses of SABA (e.g., salbutamol via spacer or nebulizer), given every 20 minutes for up to three doses in the first hour for moderate-to-severe attacks
Early systemic corticosteroids (oral prednisolone or IV methylprednisolone), which reduce relapse and hospital admission
Inhaled ipratropium bromide (an anticholinergic) added to SABA in the emergency department for moderate-to-severe exacerbations
IV magnesium sulfate for severe exacerbations not responding to initial therapy (generally reserved for children aged 2 years and older)
Admission criteria: persistent hypoxia, poor response after 1-2 hours of treatment, inability to tolerate oral intake or medication, or a history of prior severe/near-fatal attacks
A silent chest, cyanosis, exhaustion, or a confused or drowsy child are red flags for impending respiratory failure and mandate immediate escalation, not simply more bronchodilator.
Spacer and Inhaler Technique
Because inhaler technique failure is a common, correctable cause of "poorly controlled" asthma, know the following:
A spacer (valved holding chamber) should be used with every pressurized metered-dose inhaler (pMDI) in children -- it removes the need to coordinate actuation with inhalation, improves lung deposition, and reduces oropharyngeal deposition (and thus oral thrush with ICS).
Infants and toddlers who cannot form a seal around a mouthpiece use a spacer with an attached face mask ; children old enough to cooperate (roughly age 4-5 and older) transition to a spacer with a mouthpiece.
Each puff should be actuated into the spacer one at a time, followed by five to six tidal breaths (or a single deep breath and hold, in cooperative older children) before the next puff.
A nebulizer is not inherently superior to a pMDI-plus-spacer for delivering bronchodilator -- for mild-to-moderate exacerbations, pMDI with spacer is equally effective and preferred, with nebulizers reserved for severe distress or a child unable to use a spacer effectively.
After ICS use, rinsing the mouth (and regularly washing the face mask or spacer) reduces local side effects such as oral candidiasis and hoarseness.